Dana M. Alexander
Chief Technical OfficerMr. Dana M. Alexander serves as Chief Technical Officer of Obsidian Therapeutics, Inc. since April 2024. He served as Senior Vice President of Technical Operations at AlloVir, Inc. since 2020. Mr. Alexander served as Chief Operations Officer of Anika Therapeutics Inc. from April 04, 2016 to January 12, 2018. Mr. Alexander has various leadership roles at Genzyme Corporation. From 2011 to 2016, Mr. Alexander served as Senior Director of Biologics Manufacturing Operations, heading manufacturing at Genzyme's flagship biologics plant, including overseeing production planning and execution, getting new manufacturing capacity on-line and implementing new production and quality systems. Mr. Alexander held roles as at Thermo Fisher Scientific (Brammer Bio) and Chief Operations Officer at Sanofi Genzyme. In his tenure at Genzyme Corporation, Mr. Alexander also held other leadership roles and provided operational oversight for the construction, start-up and approval of a new cGMP cell culture facility, managed Chemistry, Manufacturing and Control (CMC) activities for a variety of late stage and commercial products and led operation product teams across complex supply chains to deliver global clinical and commercial supply requirements. Mr. Alexander holds a B.S. in chemical engineering from Northeastern University and an M.B.A. from Boston University.
Positions
- Company NameObsidian Therapeutics, Inc.Stock CodeOBXPositionChief Technical Officer
